The drug-induced immune hemolytic anemia market is estimated to secure a valuation of US$ 7.8 billion in 2023 and is estimated to rise to US$ 13.4 billion by 2033. The market is anticipated at a CAGR of 5.6% during the forecast period. The factors accelerating the demand for drug-induced immune hemolytic anemia are as follows-
| Data Points | Key Statistics |
|---|---|
| Expected Market Value in 2023 | US$ 7.8 billion |
| Projected Market Value in 2033 | US$ 13.4 billion |
| Growth Rate (2023 to 2033) | CAGR of 5.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
Some of the leading players operating in the drug-induced immune hemolytic anemia market are ARUP laboratories, Cyprotex, Creative Biolabs, Machaon Diagnostics, F-Hoffman LaRoche Ltd, Baxter International, Pfizer Inc, Zydus Cadila, Amneal Pharmaceutical, Incyte Corp among others.
The drug-induced immune hemolytic anemia market is expected to grow in the coming years. The increasing demand for effective drugs and an increasing number of clinical hemolysis are expected to drive market growth during the forecast period. Several start-ups have entered the drug-induced immune hemolytic anemia market with innovative products with the use of new technology.
Market players are focusing on strategic activities to increase their market share. The major players in the market are using different strategies like acquisitions, mergers, and partnerships to increase their brand presence. Some of the developments from the market are listed below
According to the latest research by FMI, Drug-Induced Immune Hemolytic Anemia is set to witness a growth CAGR of 8.4% during the year 2023 to 2033. The drug-induced immune hemolytic anemia is a rare cause of anemia often associated with poor outcomes including organ failure and even death.
The development of drug-induced immune hemolytic anemia is principally due to antibody development. The drug-induced immune hemolytic anemia market is expected to grow at a moderate pace due to the development and discovery of new drugs and the rising application of pharmacovigilance for drug imputability. The most common agents for drug-induced immune hemolytic anemia are cephalosporin and penicillin.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The number of drugs and their suggested mechanisms associated with drug-induced immune hemolytic anemia have witnessed a significant change over the past 4 decades in terms of number of implicated drugs. According to the American Society of Hematology, a reported number of 125 drugs are associated with drug-induced immune hemolytic anemia as per 2017 data of reviewed publications.
The three groups of drugs identified as predominant were antimicrobials which accounted for 42% of the implicated drugs, anti-inflammatory (15%) and anti-neoplastics (11%). The advancements in clinical pharmacology and the increasing number of reviewed case-based studies on the cause and mechanisms of drug-induced immune hemolytic anemia have resulted as drivers in case identification and timely drug withdrawal and hence are set to increase the business growth.
The clinical expression of drug-induced immune hemolytic anemia is generally mild, but it is also witnessed to develop into acute severe hemolytic anemia and even death. The increasing number in the reports of second and third generation cephalosporin which lead to clinical hemolysis are set to act as augmentative factors for the drug-induced immune hemolytic anemia.
The principal cases of drug-induced immune hemolytic anemia are identified after post-operative conditions. The region of North America holds a significant share in the identification and measures for mitigation and improvement of patient health during this period and will continue to do so over the forecast period.
This is facilitated by the presence of advanced healthcare infrastructure, robust pharmacovigilance programs and high participation of providers in clinical programs on drug-induced immune hemolytic anemia. The American Association of Blood Banks is an active moderator of drug-induced immune hemolytic anemia market.
The outlook for drug-induced immune hemolytic anemia in the European region is expected to show a moderate influence over the forecast period. This is associated with the development of appropriate clinical guidelines by British Society for Hematology and management of drug-induced immune hemolytic anemia in post-operative situations.
The key companies operating in Drug-Induced Immune Hemolytic Anemia are
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Explore Healthcare Insights
View Reports
Drug-Induced Immune Hemolytic Anemia Market
